CNS Pharmaceuticals, Inc. (CNSP)
2025-06-30 | ||||
|---|---|---|---|---|
| Research and development | 1,167,045 | |||
| General and administrative | 1,242,340 | |||
| Total operating expenses | 2,409,385 | |||
| Loss from operations | -2,409,385 | |||
| Interest income | 38,609 | |||
| Interest expense | 4,185 | |||
| Total other income (expense) | 34,424 | |||
| Net loss | -2,374,961 | |||
| Loss per share - basic | -6.42 | |||
| Loss per share - diluted | -6.42 | |||
| Weighted average shares outstanding - basic | 370,127 | |||
| Weighted average shares outstanding - diluted | 370,127 | |||